

- Fever, **123**. *See also* Acute febrile illness; Fever of unknown origin (FUO)
 approach to the patient, 125
 in autoimmune/autoinflammatory disease, 126, 126t
 central, 1773
 in coma, 1773
 factitious, 138
 fraudulent, 138
 vs. hyperthermia, 124
 hypothalamic, 124
 hypoxia and, 248
 with myalgia, 1312t, 1317–1319
 pathogenesis of, 124–125, 125f
 Pel-Ebstein, 126
 in pregnancy, 50
 quadriplegic, 2660
 with rash, **25e-1**, **127**, 128–134t, 369–370, 998.
See also Rash
 in recipient of anticytokine therapy, 125
 recurrent, 126, 139–140, 140t. *See also*
 Hereditary recurrent fever syndromes
 relapsing. *See* Relapsing fever
 in returned traveler, 801–802, 802t
 in rheumatic fever, 2152
 transfusion-related, 138e-4–5
 treatment of, 126
 water loss in, 95e-1
- Feverfew, 404t
- Fever of unknown origin (FUO). *See also* Acute febrile illness
 approach to the patient, 139f
 first-stage diagnostic tests, 138–139
 later-stage diagnostic tests, 141
 PET, 140–141
 in recurrent fever, 139–140
 scintigraphy, 140
 definition of, 135
 differential diagnosis of, 136–138
 etiology of, 135–136, 136t
 global considerations in, 136, 136t
 prognosis of, 142
 recurrent, 140t
 treatment of, 141
- Fever syndrome, 372e-8t
- FFAs (free fatty acids), 265e-10
- FFI (fatal familial insomnia), 191, 453e-1t, 453e-4
- FGF8* gene mutations, 2364t
- FGF23* (fibroblast growth factor 23), 333e-3, 612, 1815
- FGFR1* gene mutations
 in eosinophilia, 135e-7, 135e-7t
 in hypogonadotropic hypogonadism, 2363, 2364t
 in lung cancer, 507t, 509
- FGFR1*-mutated eosinophilia, 135e-8
- FGFR2* gene mutations, 435
- FGFR3* gene mutations, 426e-7, 2512
- FGFR23* gene mutations, 2458
- FHH. *See* Familial hypocalciuric hypercalcemia (FHH)
- Fialuridine, 2025
- Fiber, dietary. *See* Dietary fiber
- Fiberoptic bronchoscopy, 512, 1667, 1710
- Fibric acid derivatives (fibrates)
 adverse effects of, 462e-19, 462e-20t, 2447, 2448t
 for hypertriglyceridemia, 2447, 2448t
 for metabolic syndrome, 2453
- Fibrillar, 372e-24t, 2157t
- Fibrillary-immunotactoid glomerulopathy, 1835t, 1845
- Fibrillation potentials, EMG, 155, 442e-4, 442e-4f
- Fibrillin aggregates, 2507
- Fibrin, 402, 725, 745, 746f
- Fibrin clot, 401, 401f
- Fibrin degradation products, 737
- Fibrin(ogen) degradation products, 402, 402f, 407
- Fibrinogen
 deficiency of, 404, 733t
 functions of, 402, 746f
- Fibrinolysis
 atherosclerosis and, 8–9
 in DIC, 737, 737f
 regulation of, 402–403, 402f
 thrombosis and, 744
- Fibrinolytic drugs, 757
 action of, 757f, 758
 for acute limb ischemia, 1646
 adverse effects of, 1605
 alteplase. *See* Alteplase (rtPA)
 anistreplase, 758
 contraindications to, 1605, 1636
 in development, 759–760
 indications for, 757
 for myocardial infarction, 1604f, 1605
 for pulmonary embolism, 1636
 reteplase. *See* Reteplase
 streptokinase. *See* Streptokinase
 tenecteplase. *See* Tenecteplase
 urokinase, 758–759
- Fibroblast growth factor-19 (FGF-19), 268
- Fibroblast growth factor-23 (FGF-23), 333e-3, 1815, 2455, 2458
- Fibroblasts, 102e-3
- Fibrocystic disease, of breast, 526
- Fibrocystin/polyductin, 1851f, 1853
- Fibrodysplasia ossificans progressiva, 426e-7t, 426e-8
- Fibroelastoma, papillary, 289e-2
- Fibrogenesis imperfecta ossium, 426e-6
- Fibroids, uterine (leiomyoma), 596
- Fibrolamellar hepatocellular carcinoma, 552
- Fibromas
 cardiac, 270e-24, 270e-24f, 289e-2
 ovarian, 594
 paraneoplastic syndromes in, 609t
- Fibromuscular dysplasia, 1617, 1627, 1645, 2567
- Fibromyalgia, **2238**
 approach to the patient, 2240
 clinical features of, 2199, 2221, 2238–2239, 2238f
 definition of, 2238
 diagnosis of, 2239, 2239t
 differential diagnosis of, 462e-2, 1152, 2239, 2239t
 epidemiology of, 2238
 genetic considerations in, 2239–2240
 in HIV infection, 1261
 overlapping syndromes, 2239
 physiology of, 2240
 tender point assessment in, 2238, 2238f
 treatment of, 2240, 2240t
- Fibronectin, 145e-3, 372e-24t
- Fibronectin-binding protein, 817
- Fibrosis
 airway, in asthma, 1674
 pulmonary. *See* Pulmonary fibrosis
 in systemic sclerosis, 2157
- Fibrous dysplasia, 426e-6–7, 426e-6f. *See also*
 McCune-Albright syndrome
- Fibrous histiocytoma, malignant, 119e-1.
See also Soft tissue sarcoma
- Fick method, cardiac output measurement, 1462–1463
- Fidaxomicin, 860, 860t
- Fiduciary obligations, 17e-2
- Fifth disease. *See* Erythema infectiosum (fifth disease)
- Figurate skin lesions, 354–355, 356t
- FIHP (familial isolated hyperparathyroidism), 2340
- Filaggrin, 344
- Filamentous hemagglutinin, 1021, 1022
- Filaria dance sign, 1419
- Filariasis, lymphatic. *See* Lymphatic filariasis
- Filiform warts, 351
- Filoviruses
 gene expression and replication in, 214e-4
 genome of, 1323
 global considerations in, 782
 phylogeny/evolution of, 1324f
 structure of, 214e-2t, 214e-3f, 1323
 taxonomy of, 1323f
- Filovirus infections. *See also* Ebola virus disease; Marburg virus disease
 clinical features of, 1327–1328, 1327t
 complications of, 1328
 control and prevention of, 1328–1356
 diagnosis of, 1328
 pathogenesis of, 1326–1327
 prognosis of, 1328
 treatment of, 1328
- FIM (Functional Independence Measure), 78t
- Fimbriae. *See* Pili (fimbriae), bacterial
- Financial incentives, 17e-3
- Finasteride
 for androgenetic alopecia, 355t
 for hirsutism, 335
 lower urinary tract symptoms, 7e-4
 for prostate cancer prevention, 478, 580
- Fine-needle aspiration biopsy, 103e-2, 409
- Finger(s)
 clubbing of. *See* Clubbing, of digits
 in gouty arthritis, 436e-2f
 in psoriatic arthritis, 2176, 2176f
- Finger anomia, 179
- Finger-to-nose testing, 2539
- Fingolimod, 2669–2670, 2669t
- Finkelstein's sign/test, 2220–2221, 2248
- Fire ants, 2116, 2749
- Fire coral envenomation, 2741
- First-pass elimination/effect, 33–34, 33f, 935
- FISH. *See* Fluorescence in situ hybridization (FISH)
- Fish, nematode infections from, 1412, 1416
- Fisher's syndrome, 41e-1v, 209
- Fish-eye disease, 2445
- Fish meal worker's lung, 1681t
- Fish odor syndrome (trimethylaminuria), 96e-6
- Fish oils. *See* Omega-3 fatty acids (fish oils)
- Fish tapeworm (*Diphyllobothrium latum*), 245e-2t, 645, 1434
- Fissure(s), anal, **1978**
- Fissured (scrotal) tongue, 46e-5f, 241t
- Fistula(s). *See also* Arteriovenous fistula
 coronary artery, 1523
 gallbladder, 2081
 hepatobronchial, 1365
 pancreaticopleural, 2095f
- Fistula in ano, 1111, **1978**
- Fitz-Hugh–Curtis syndrome (perihepatitis), 877, 1169
- Fitzpatrick skin types, 386, 386t
- 5-day fever. *See* Trench fever
- Fixed drug eruption, 381, 382f
- Flaccidity, 154
- Flagella
 of bacteria, 145e-2f, 145e-3, 145e-5
 of *P. aeruginosa*, 1043, 1043t
- Flail leaflet, 51e-4
- FLAIR. *See* Fluid-attenuated inversion recovery (FLAIR) MRI
- Flatus/flatulence, 285, 1945, 1965–1966
- Flat warts, 351
- Flatworm infections. *See* Cestodes/cestode infections; Trematodes/trematode infections
- Flaviviruses
 gene expression and replication in, 214e-4
 global considerations in, 782
 reservoirs and vectors of, 1305, 1306–1307t
 structure of, 214e-2t, 214e-3f
- Flavivirus infections
 clinical syndromes of, 1306–1307t
 dengue fever. *See* Dengue fever
 geographic distribution of, 1311–1312t
 Japanese encephalitis, 1315
 St. Louis encephalitis, 1315
 tick-borne viral encephalitis, 1315–1316
 viral hemorrhagic fevers, 1322–1323
 West Nile virus. *See* West Nile virus infection
 yellow fever, 8, 1322–1323
- Flavoenzymes, 96e-3
- Flavonoids, **96e-6**
- Flavopiridol, 102e-4f
- Flavor enhancers, 216